



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents, Mail Stop DD, PO Box 1450,
Alexandria, VA 22313 on October 2, 2003.



INFORMATION DISCLOSURE
STATEMENT
Patent Application
Docket No. ARYX-112XCD1
Serial No. 10/643,699

David Saliwanchik
David R. Saliwanchik, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Pascal Druzgala, Peter G. Milner, Jurg R. Pfister, Xiaoming Zhang
Serial No. : 10/643,699
Filed : August 18, 2003
For : Materials and Methods for the Treatment of Hypertension and Angina

Commissioner for Patents
Mail Stop DD
P.O. Box 1450
Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.97 and §1.98(d), the applicants would like to bring to the attention of the Examiner, the references cited in the following patent application:

U.S. Serial No. 10/269,139, filed October 10, 2002, now U.S. Patent No. 6,608,097.

The subject application, Serial No. 10/643,699 claims the benefit under 35 USC §120 of the filing date of the above application. The applicants respectfully request that the copies of references supplied in the Information Disclosure Statements of the above-mentioned application, as well as the references cited during prosecution thereof, be made of record in the 10/643,699 application. As copies of all of the references filed in the parent application, and cited on the attached form PTO/SB/08, will be found in the parent casenfile, copies of those references are not provided herewith.

The applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



David R. Saliwanchik
Patent Attorney
Registration No. 31,794
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: 2421 N.W. 41st Street, Suite A-1
Gainesville, Florida 32606-6669

DRS/ba

Attachment: Form PTO/SB/08



Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (10-01)

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

Application Number	10/643,699
Filing Date	August 18, 2003
First Named Inventor	Pascal Druzgala
Group Art Unit	
Examiner Name	

Attorney Docket Number ARYX-112XCD1

NON PATENT LITERATURE DOCUMENTS


Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	Bursztyn, M., et al., "Mibepradil, a novel calcium antagonist, in elderly patients with hypertension: Favorable hemodynamics and pharmacokinetics", <i>American Heart Journal</i> , August 1997, pp. 238-47, Vol. 134, No. 2, Pt. 1, Mosby-Year Book, Inc.	
	R2	De Ponti, F., et al., "QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience", <i>Eur J Clin Pharmacol</i> , 2000, pp. 1-18, Vol. 56, Springer-Verlag.	
	R3	Dershwitz, M., et al. "Pharmacokinetics and Pharmacodynamics of Remifentanil in Volunteer Subjects with Severe Liver Disease", <i>Anesthesiology</i> , April 1996, pp. 812-20, Vol. 84, No. 4, American Society of Anesthesiologists, Inc., Lippincott-Raven Publishers.	
	R4	Kostrubsky, V., et al., "The Role of Conjugation in Hepatotoxicity of Troglitazone in Human and Porcine Hepatocyte Cultures", <i>Drug Metabolism and Disposition</i> , 2000, pp. 1192-97, Vol. 28, No. 10, The American Society for Pharmacology and Experimental Therapeutics.	
	R5	RUTLEDGE et al. "The Binding Interactions of Ro 40-5967 at the L-type Ca ²⁺ Channel in Cardiac Tissue" <i>European Journal of Pharmacology</i> , 1995, pp. 155-158, Vol. 280.	
	R6	Selnick, H., et al., "Class-III Antiarrhythmic Activity in Vivo By Selective Blockade of the Slowly Activating Cardiac Delayed Rectifier Potassium Current I _{Ks} by (R)-2-(2,4-Trifluoromethyl)-N-[2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl] acetamide," <i>J. Med. Chem.</i> , November 1997, pp. 3865-8, Vol. 40, No. 24, American Chemical Society.	
	R7	Vandenberg, J., et al., "HERG K ⁺ channels: friend and foe", <i>Trends in Pharmacological Sciences</i> , May 2001, pp. 240-6, Vol. 22, No. 5, Elsevier Science, Ltd.	
	R8		
	R9		
	R10		
	R11		
	R12		

Examiner Signature	Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known
Sheet	1	of	2	Application Number
				10/643,699
				Filing Date
				August 18, 2003
				First Named Inventor
				Pascal Druzgala
				Art Unit
				Examiner Name
				Attorney Docket Number
				ARYX-112XCD1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
U1		US-4,808,605	02-28-1989	Branca et al.	All
U2		US-5,620,975	04-15-1997	Clozel et al.	All
U3		US-			
U4		US-			
U5		US-			
U6		US-			
U7		US-			
U8		US-			
U9		US-			
U10		US-			
U11		US-			
U12		US-			
U13		US-			
U14		US-			
U15		US-			
U16		US-			
U17		US-			
U18		US-			
U19		US-			
U20		US-			

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Country Code ³	- Number ⁴ - Kind Code ⁵ (if known)		
	F1	EP	0 524 512 A2	01-27-1993	F. HOFFMANN-LA ROCHE AG
	F2	JP	11 035483 A (Abstract only)	02-09-1999	NIPPON KAYAKU CO. LTD.
	F3				
	F4				
	F5				
	F6				
	F7				
	F8				
	F9				
	F10				

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.